LPL Financial’s Mustang Bio MBIO Stock Holding History

LPL Financial’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20	Closed	-$9K	–	4472
2022 Q2	$9K	Hold	20	–	–	﹤0.01%	4389
2022 Q1	$15K	Buy	+20	New	+$16.4K	﹤0.01%	4138

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPL Financial's MBIO Position: Q3 2022 in Review

LPL Financial sold out of Mustang Bio (MBIO) in Q3 2022, closing a stake of 20 shares — an estimated $9K sold.

LPL Financial first reported a position in MBIO in Q1 2022 and held it in 2 quarters. The position peaked at $15K in Q1 2022. 67 funds tracked by Wall St. Rank hold MBIO as of Q3 2022.

LPL Financial reported no remaining Mustang Bio position as of Q3 2022 after selling out during the quarter.
LPL Financial sold 20 Mustang Bio shares in Q3 2022, an estimated $9K.
LPL Financial first reported a position in Mustang Bio in Q1 2022 and held it in 2 quarters.
LPL Financial's Mustang Bio position peaked at $15K in Q1 2022.
67 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2022.

Based on LPL Financial's 13F filing for Q3 2022, filed 14 Nov 2022.